Dopamine agonists in schizophrenia: a review

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Schizophrenia pathogenesis is complex, but dopaminergic hyperactivity is implicated in positive symptoms.
• Dopamine synthesis and release are regulated by autoreceptors via negative feedback.
• Existing research on dopamine autoreceptor agonists in schizophrenia yields inconsistent results.

Purpose of the Study:

• To investigate the therapeutic effects of dopamine autoreceptor agonists in schizophrenia.
• To assess the impact of nonselective and selective dopamine autoreceptor agonists on positive and negative symptoms.

Main Methods:

• Review of investigations on autoreceptor-nonselective and selective dopamine agonists.
• Analysis of clinical trials testing agents like pramipexole, roxindole, and talipexole.
• Evaluation of effects on positive symptomatology (e.g., hallucinations) and negative symptomatology (e.g., affective flattening).

Main Results:

• Autoreceptor-selective agonists did not significantly improve positive symptoms of schizophrenia.
• Some evidence suggests nonselective dopamine autoreceptor agonists may mildly improve negative symptoms like affective flattening and avolition.
• Findings are based on open-label and limited placebo-controlled trials.

Conclusions:

• Current evidence does not support the use of autoreceptor-selective dopamine agonists for positive schizophrenia symptoms.
• Dopamine autoreceptor agonists may offer potential for treating negative symptoms, but require further investigation.
• More rigorous, double-blind, placebo-controlled studies with adequate duration are necessary to validate these findings.